FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Center | Date | Time | Location |
---|---|---|---|
CDRH | March 25, 2004 | 8 a.m. - 5 p.m. | Hilton Washington,
DC North |
Agenda:
The committee will discuss, make recommendations, and vote on a premarket approval
application (PMA) for an injectable device intended for use in the correction
of lipoatrophy of the face in human immunodeficiency virus (HIV) positive patients.
Background material and meeting information will become available no later than the day before the meeting (Simply select the appropriate committee link).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by March 15, 2004. On March 25, 2004, oral presentations from
the public will be scheduled for approximately 1 hour at the beginning of committee
deliberations and for approximately 1 hour near the end of the committee deliberations.
Time allotted for each presentation may be limited. Those desiring to make formal
oral presentations should notify the contact person before March 15, 2004, and
submit a brief statement of the general nature of the evidence or arguments
they wish to present, the names and addresses of proposed participants, and
an indication of the approximate time requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised that the agency
is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Shirley Meeks, Conference Management Staff, at 301-594-1283,
ext. 105, at least 7 days in advance of the meeting.
Contact Person:
David Krause, Center for Devices and Radiological Health (HFZ-410),
Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-3090,
ext. 141, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572
in the Washington, DC area), code 3014512519. Please call the Information Line
for up-to-date information on this meeting.
[ Full FR Notice ]